相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-Term Remission of Acromegaly after Octreotide Withdrawal Is an Uncommon and Frequently Unsustainable Event
Alessandra Casagrande et al.
NEUROENDOCRINOLOGY (2017)
Remission of acromegaly after treatment withdrawal in patients controlled by cabergoline alone or in combination with octreotide: results from a multicenter study
A. Casagrande et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2017)
High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study
Andrea Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly
Rudolf Fahlbusch et al.
PITUITARY (2017)
Biochemical investigations in diagnosis and follow up of acromegaly
Katharina Schilbach et al.
PITUITARY (2017)
New medical therapies on the horizon: oral octreotide
Nienke R. Biermasz
PITUITARY (2017)
A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry
Roberto Salvatori et al.
PITUITARY (2017)
Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study
Shigeyuki Tahara et al.
ENDOCRINE JOURNAL (2017)
Treatment of acromegaly patients at the Federal University of Triangulo Mineiro (UFTM): Experience Report
Maria de Fatima Borges et al.
CLINICS (2017)
CLINICAL OUTCOMES AND SELF-REPORTED SYMPTOMS IN PATIENTS WITH ACROMEGALY: AN 8-YEAR FOLLOW-UP OF A LANREOTIDE STUDY
Shafaq Khairi et al.
ENDOCRINE PRACTICE (2017)
The History of Acromegaly
Wouter W. de Herder
NEUROENDOCRINOLOGY (2016)
Growth Hormone Dynamics in Healthy Adults Are Related to Age and Sex and Strongly Dependent on Body Mass Index
Ferdinand Roelfsema et al.
NEUROENDOCRINOLOGY (2016)
Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center
Monica Livia Gheorghiu et al.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2016)
Optimizing Blood Sampling Protocols in Patients With Acromegaly for the Estimation of Growth Hormone Secretion
Ferdinand Roelfsema et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naive active acromegaly
Jan-Shun Chang et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2016)
Monotherapy with lanreotide depot for acromegaly: long-term clinical experience in a pituitary center
Babak Torabi Sagvand et al.
PITUITARY (2016)
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study
Marcello D. Bronstein et al.
BMC ENDOCRINE DISORDERS (2016)
Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study
Manuel Puig-Domingo et al.
ENDOCRINOLOGIA Y NUTRICION (2016)
Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response
Leandro Kasuki et al.
Archives of Endocrinology Metabolism (2016)
Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
Herbert A. Schmid et al.
ENDOCRINE (2016)
Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study
Sebastian J. C. M. M. Neggers et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors
Ilan Shimon et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Treatment Outcome Results from the Bulgarian Acromegaly Database: Adjuvant Dopamine Agonist Therapy is Efficient in Less than One Fifth of Non-irradiated Patients
S. Vandeva et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2015)
Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial
Shlomo Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models
Meindert Danhof
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2015)
Discontinuation of somatostatin analogs while acromegaly is in long-term remission
Esra Hatipoglu et al.
PITUITARY (2015)
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
Michael Sheppard et al.
PITUITARY (2015)
Octreotide LAR treatment of acromegaly in real life: long-term outcome at a tertiary care center
Ana Laura Espinosa-de-los-Monteros et al.
PITUITARY (2015)
Acromegaly and pregnancy: a prospective study
Monike Dias et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial
S. L. Fougner et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial
Philippe J. Caron et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly: An Endocrine Society Clinical Practice Guideline
Laurence Katznelson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
A. Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Pharmacokinetics, Pharmacodynamics, and Safety of Pasireotide LAR in Patients With Acromegaly: A Randomized, Multicenter, Open-Label, Phase I Study
Stephan Petersenn et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Common misconceptions about data analysis and statistics
Harvey J. Motulsky
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2014)
Biochemical and quality of life responses to octreotide-LAR in acromegaly
Ruth Mangupli et al.
PITUITARY (2014)
Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry
Roberto Salvatori et al.
PITUITARY (2014)
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
Stephan Petersenn et al.
PITUITARY (2014)
Clinical experiences and success rates of acromegaly treatment: the single center results of 62 patients
Mehtap Evran et al.
BMC ENDOCRINE DISORDERS (2014)
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
Monica R. Gadelha et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism
Akira Shimatsu et al.
ENDOCRINE JOURNAL (2013)
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 Update
Laurence Katznelson et al.
Endocrine Practice (2013)
Efficacy and Safety of an Octreotide Implant in the Treatment of Patients With Acromegaly
Carla Chieffo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
A Comprehensive Study of Clinical, Biochemical, Radiological, Vascular, Cardiac, and Sleep Parameters in an Unselected Cohort of Patients With Acromegaly Undergoing Presurgical Somatostatin Receptor Ligand Therapy
Anand K. Annamalai et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Pegvisomant and cabergoline combination therapy in acromegaly
I. Bernabeu et al.
PITUITARY (2013)
Reference values for serum levels of insulin-like growth factor 1 (IGF-1) and IGF-binding protein 3 (IGFBP-3) in the West Black Sea region of Turkey
Berrak Guven et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2013)
A SUBCUTANEOUS OCTREOTIDE HYDROGEL IMPLANT FOR THE TREATMENT OF ACROMEGALY
Monica R. Gadelha et al.
ENDOCRINE PRACTICE (2012)
Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?
Claudia Ramirez et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Effective Combination Treatment with Cabergoline and Low-Dose Pegvisomant in Active Acromegaly: A Prospective Clinical Trial
C. E. Higham et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Pharmacodynamic Modeling of the Effects of Lanreotide Autogel on Growth Hormone and Insulin-Like Growth Factor 1
Maria J. Garrido et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Preoperative Lanreotide Treatment Improves Outcome in Patients with Acromegaly Resulting from Invasive Pituitary Macroadenoma
Z-Q Li et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2012)
Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
Yasemin Tutuncu et al.
PITUITARY (2012)
The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy
Zelija Velija-Asimi
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2012)
Normal values of serum IGF-1 in adults: results from a Brazilian population
Pedro Weslley Rosario
ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA (2010)
Mortality in acromegaly: A meta analysis
O. M. Dekkers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Acromegaly
Philippe Chanson et al.
ORPHANET JOURNAL OF RARE DISEASES (2008)
The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly
A Pokrajac et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Sex-steroid control of the aging somatotropic axis
JD Veldhuis et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2005)
Postoperative evaluation of patients with acromegaly: Clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels
RA Feelders et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
分享论文
